Skip to main content
Clinical Trials/NCT03959618
NCT03959618CompletedNot Applicable

Mono-centric, Prospective, Non-Interventional Study of Quantitative and Qualitative Analysis of Dietary Supplement Taken With Chemotherapy Treatments in Patients With Adjuvant Breast Cancer Taken Care of at the Day Hospital

Institut Cancerologie de l'Ouest1 site in 1 country200 target enrollmentStarted: April 2, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
evaluate quantitatively the use of dietary supplements in patients during IV chemotherapy

Study Overview

Brief Summary

More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.

In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.

At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.

Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).

Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.

Detailed Description

  • Determine the quantitative impact of the use of dietary supplements by patients with breast cancer and treated in a neo-adjuvant and/or adjuvant condition by IV chemotherapy in day hospital.
  • Determine an over-risk of disruption of liver balance in the population of patients taking Desmodium.
  • Gather a critical mass of relevant information with the objective of carrying out the evaluation and analysis of cancer care practices related to the intake of dietary supplements.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • breast cancer treated by intra-venous chemotherapy
  • inclusion at the last cycle (cure)
  • all chemotherapy cycles realised at ICO

Exclusion Criteria

  • no breast cancer
  • metastatic breast cancer
  • not all chemotherapy cycles realised at ICO
  • patient who has not finished his chemotherapy

Outcomes

Primary Outcomes

evaluate quantitatively the use of dietary supplements in patients during IV chemotherapy

Time Frame: 12 months

rate of patients taking a dietary supplement

Secondary Outcomes

  • Description of dietary supplements taken(12 months)
  • Evaluate the impact of taking Desmodium between the first and last cycle of treatment(12 months)

Investigators

Sponsor
Institut Cancerologie de l'Ouest
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials